Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Acquir Immune Defic Syndr ; 96(3): 290-298, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38905478

RESUMEN

BACKGROUND: In Kenya, of the 82,000 children living with HIV, only 59% are receiving ART and 67% are virally suppressed. Early in the COVID-19 pandemic, the Ministry of Health recommended 3 multimonth dispensing (3MMD) of ART to all people living with HIV, including children. This study assesses the association between 3 MMD and clinical outcomes among children in Western Kenya. SETTINGS: and Methods: We conducted a retrospective cohort study using routinely collected deidentified patient-level data from 43 facilities in Kisii and Migori Counties. The study included children aged 2-9 years who had been previously initiated on ART and sought HIV services between March 01, 2020, and March 30, 2021. We used generalized linear models with Poisson regression models to assess the association between MMD on retention at 6 months and viral suppression (<1000 copies/mL). RESULTS: Among the 963 children, 65.2% were aged 5-9 years and 50.7% were female patients. Seventy-eight percent received 3MMD at least once during the study period. Children who received 3MMD were 12% (adjusted risk ratio [aRR] 1.12, 95% CI: 1.01 to 1.24) more likely to be retained and 22% (aRR 1.22, 1.12 to 1.34) more likely to be virally suppressed than those on <3MMD. When stratified by viral suppression at entry, the association between 3MMD and retention (aRR 1.22, 95% CI: 1.02 to 1.46) and viral suppression (aRR 1.76, 95% CI: 1.30-2.37) was significant among individuals who were unsuppressed at baseline. CONCLUSIONS: 3MMD was associated with comparable or improved HIV health outcomes among children.


Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , Humanos , Infecciones por VIH/tratamiento farmacológico , Preescolar , Kenia/epidemiología , Femenino , Niño , Masculino , Estudios Retrospectivos , Fármacos Anti-VIH/uso terapéutico , COVID-19/epidemiología , Carga Viral , Continuidad de la Atención al Paciente , Estudios de Cohortes , SARS-CoV-2
2.
AIDS ; 2024 May 31.
Artículo en Inglés | MEDLINE | ID: mdl-38819841

RESUMEN

OBJECTIVE: Kenya ART guidelines recommend three sessions of enhanced adherence counselling (EAC) following detectable viral load (VL). The objective of this study was to assess completion of EAC sessions and factors associated with viral re-suppression amongst adolescents and young persons (AYPs) with persistent viremia in Western Kenya. METHODS: A retrospective analysis of routinely collected data abstracted from VL registers was done. AYP with persistent viremia (consecutive VL ≥ 1,000 copies/ml) between October 2017 to September 2019 were followed for 12 months; those with >1 follow-up VL results were analyzed. EAC was satisfactory if ≥3 sessions attended, barriers identified and addressed. Morisky scores 0 and ≥1 indicated optimal and sub-optimal adherence respectively. Logistic regression models were used to assess predictors of viral load suppression (VLS). RESULTS: Of 124 AYPs with persistent viremia, 118(95.2%) had documented follow up VL results and 119(96.0%) completed three EAC sessions. Overall, 55(47%) clients re-suppressed during the study period. AYPs who had satisfactory EAC sessions had higher odds of achieving VLS (odds ratio [OR] = 3.7, 95% confidence interval [CI]: 1.6-8.1). Similarly, AYPs with an optimal adherence had eight times (OR = 8.1, 95%CI: 3.5-18.5) higher odds of achieving VLS, and those who were suppressed at 6 months post ART initiation had higher odds of achieving VLS at 12-months (OR = 2.5, 95%CI:1.1-5.8). CONCLUSION: Satisfactory EAC sessions and optimal ART adherence was strongly associated with viral re-suppression among AYPs with persistent viremia. Continued support to EAC intervention is critical to improve treatment outcome among AYP living with HIV.

3.
Pharmaceut Med ; 33(2): 145-157, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-31933250

RESUMEN

BACKGROUND: Adverse drug reactions (ADRs) are a source of concern in healthcare as they negatively affect patients. Serious adverse drug reactions (SADRs) have an even greater impact on patients and the system in terms of morbidity and financial burden. The establishment of National Pharmacovigilance Centers (NPCs) has enhanced ADR reporting in Africa. The Nigerian Pharmacovigilance Centre has been collecting ADR reports using VigiFlow since 2004. OBJECTIVE: The aim of this study was to identify and analyze SADR reports in the Nigerian VigiFlow database in order to profile the patients with SADRs, the medicines most implicated, system organ classes (SOCs) affected, outcome of such reactions, including fatalities, and ADR reporting trends over the years. We also looked at the data elements provided in the reports as a proxy measure of report quality. METHOD: We retrospectively assessed all individual case safety reports (ICSRs) received by the NPC in Nigeria and entered into VigiFlow as SADR reports between September 2004 and December 2016. We defined SADR as any untoward reaction to any medicine dose that resulted in death, required in-patient hospitalization or prolongation of existing hospitalization, resulted in congenital anomaly, persistent or significant disability/incapacity or was life-threatening. The suspected SADRs were analyzed at the Medical Dictionary for Regulatory Activities SOC and Preferred Term levels. RESULTS: A total of 11,222 ICSRs were entered into VigiFlow during the study period, of which 298 (3%) were classified as SADR reports. Adults were the most affected (244/282; 87%). The median number of medicines per report was 3 (interquartile range = 2-4.75). Nevirapine (36/336; 11%), as a single entity, was the most reported medicine. Human immunodeficiency virus (HIV) infection affected 128/232 (55%) of those with SADRs. There was no statistically significant association between the number of reactions per report and sex of the patients (p = 0.280), their age groups (p = 0.670), or the number of medicines per report (p = 0.640). Hospitalization was the most frequently cited reason for classifying a report as serious (151/276; 53%) and death was reported in 48 cases (48/283; 17%). Based on the SOC, skin and subcutaneous tissue disorders (139/550; 25%) was the most affected, while anemia (55/550; 10%) was the most reported specific reaction. A substantial number of patients (107/256; 42%) either recovered fully or were recovering from the SADRs. The number of SADR reports received varied by year with no consistent trend. CONCLUSION: There is under-reporting of ADRs in the Nigerian VigiFlow® database, particularly SADRs and those involving pediatric and geriatric age groups. Given that over half of the SADR reports involved antiretroviral drugs, it is imperative to increase the surveillance of ADRs related to this class of drugs through regular clinical assessment of reports and provision of feedback on the findings to healthcare providers. Direct consumer reporting should also be encouraged as a means of increasing ADR reporting.


Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos/tendencias , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Personal de Salud/estadística & datos numéricos , Adulto , Anciano , Anemia/inducido químicamente , Anemia/epidemiología , Fármacos Anti-VIH/efectos adversos , Antirretrovirales/efectos adversos , Causas de Muerte/tendencias , Niño , Anomalías Congénitas/epidemiología , Bases de Datos Factuales , Personas con Discapacidad/estadística & datos numéricos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Nevirapina/efectos adversos , Nigeria/epidemiología , Seguridad del Paciente/estadística & datos numéricos , Farmacovigilancia , Estudios Retrospectivos , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/epidemiología
4.
J Food Prot ; 56(5): 444-446, 1993 May.
Artículo en Inglés | MEDLINE | ID: mdl-31084136

RESUMEN

In order to establish the presence and distribution of Plesiomonas shigelloides in the Port Harcourt area, samples from different origins were examined. Standard microbiological methods were adopted for the analysis. The results showed a relatively high incidence in soil and water which are speculated to be reservoirs of the organism. A low incidence rate occurred in seafoods and humans. No P. shigelloides was detected from cattle and poultry. Although the isolation in humans was low 2.0% (8 of 400), five samples yielded P. shigelloides as the only enteropathogen. Four of the five were from diarrheic fecal samples, thus indicating the involvement of P. shigelloides in diarrhea.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...